Publications by authors named "Angeline Mariani"

Claim this Profile
T
The Latino Eyelid: Anthropometric Analysis of a Spectrum of Findings.
Constance L Fry, Thomas C Naugle, Shelley A Cole, Jonathan Gelfond, Geetha Chittoor, Angeline F Mariani

Ophthalmic Plast Reconstr Surg· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idiopathic Orbital Inflammation Associated With Relapsing Polychondritis.
Angeline F Mariani, Amina I Malik, Patricia Chevez-Barrios, Stacy V Smith, Andrew G Lee

Ophthalmic Plast Reconstr Surg· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.
James C Major, Charles C Wykoff, Daniel E Croft, Rui Wang, Angeline F Mariani

Can J Ophthalmol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Purtscher-like retinopathy associated with pemphigus vulgaris.
Angeline F Mariani, James C Major, David M Brown, Charles C Wykoff, Matthew S Benz

Retin Cases Brief Rep· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
David M Brown, Charles C Wykoff, Tien P Wong, Angeline F Mariani, Daniel E Croft

Retina· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity.
James C Major, Charles C Wykoff, Angeline F Mariani, Eric Chen, Daniel E Croft

Retina· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results.
Charles C Wykoff, David M Brown, Eric Chen, James C Major, Daniel E Croft, Angeline Mariani

Ophthalmic Surg Lasers Imaging Retina· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
David M Brown, Eric Chen, Angeline Mariani, James C Major,

Ophthalmology· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis